| Michelle L Bush, MD | |
|
128 Carnegie Row, Norwood, MA 02062-5161 | |
| (781) 762-5858 | |
| (781) 949-4343 |
| Full Name | Michelle L Bush |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Location | 128 Carnegie Row, Norwood, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679503270 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 221250 (Massachusetts) | Primary |
| Entity Name | Dermatology Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063570075 PECOS PAC ID: 7012982044 Enrollment ID: O20040901000673 |
News Archive
CompPharma, a consortium of workers' compensation pharmacy benefit managers, has compiled a directory of terms and definitions describing various aspects of the workers' compensation pharmacy industry.
AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02. The company based its fast decision on the first interim analysis of the secondary endpoints at the six month time point.
Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, is working to educate the public about hereditary cancer risk assessment and testing during Prostate Cancer Awareness Month this September.
NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of patient randomization in its Phase 3 registration study of GATTEX® (teduglutide). The double-blind, placebo-controlled safety and efficacy study, which is known as STEPS, is being conducted in patients with parenteral nutrition (PN) dependent short bowel syndrome (SBS) and is now fully randomized with 86 patients.
› Verified 7 days ago
| Entity Name | Louis Kuchnir Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871709634 PECOS PAC ID: 0143270868 Enrollment ID: O20050131000033 |
News Archive
CompPharma, a consortium of workers' compensation pharmacy benefit managers, has compiled a directory of terms and definitions describing various aspects of the workers' compensation pharmacy industry.
AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02. The company based its fast decision on the first interim analysis of the secondary endpoints at the six month time point.
Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, is working to educate the public about hereditary cancer risk assessment and testing during Prostate Cancer Awareness Month this September.
NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of patient randomization in its Phase 3 registration study of GATTEX® (teduglutide). The double-blind, placebo-controlled safety and efficacy study, which is known as STEPS, is being conducted in patients with parenteral nutrition (PN) dependent short bowel syndrome (SBS) and is now fully randomized with 86 patients.
› Verified 7 days ago
| Entity Name | Dermcare Physicians And Surgeons Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780636597 PECOS PAC ID: 9234141904 Enrollment ID: O20060620000223 |
News Archive
CompPharma, a consortium of workers' compensation pharmacy benefit managers, has compiled a directory of terms and definitions describing various aspects of the workers' compensation pharmacy industry.
AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02. The company based its fast decision on the first interim analysis of the secondary endpoints at the six month time point.
Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, is working to educate the public about hereditary cancer risk assessment and testing during Prostate Cancer Awareness Month this September.
NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of patient randomization in its Phase 3 registration study of GATTEX® (teduglutide). The double-blind, placebo-controlled safety and efficacy study, which is known as STEPS, is being conducted in patients with parenteral nutrition (PN) dependent short bowel syndrome (SBS) and is now fully randomized with 86 patients.
› Verified 7 days ago
| Entity Name | South Shore Dermatology Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992988703 PECOS PAC ID: 4789767104 Enrollment ID: O20080208000161 |
News Archive
CompPharma, a consortium of workers' compensation pharmacy benefit managers, has compiled a directory of terms and definitions describing various aspects of the workers' compensation pharmacy industry.
AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02. The company based its fast decision on the first interim analysis of the secondary endpoints at the six month time point.
Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, is working to educate the public about hereditary cancer risk assessment and testing during Prostate Cancer Awareness Month this September.
NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of patient randomization in its Phase 3 registration study of GATTEX® (teduglutide). The double-blind, placebo-controlled safety and efficacy study, which is known as STEPS, is being conducted in patients with parenteral nutrition (PN) dependent short bowel syndrome (SBS) and is now fully randomized with 86 patients.
› Verified 7 days ago
| Entity Name | Nesc Macipa Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467791665 PECOS PAC ID: 2062659071 Enrollment ID: O20130513000011 |
News Archive
CompPharma, a consortium of workers' compensation pharmacy benefit managers, has compiled a directory of terms and definitions describing various aspects of the workers' compensation pharmacy industry.
AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02. The company based its fast decision on the first interim analysis of the secondary endpoints at the six month time point.
Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, is working to educate the public about hereditary cancer risk assessment and testing during Prostate Cancer Awareness Month this September.
NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of patient randomization in its Phase 3 registration study of GATTEX® (teduglutide). The double-blind, placebo-controlled safety and efficacy study, which is known as STEPS, is being conducted in patients with parenteral nutrition (PN) dependent short bowel syndrome (SBS) and is now fully randomized with 86 patients.
› Verified 7 days ago
| Entity Name | Nesc Steward Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538575386 PECOS PAC ID: 3173848355 Enrollment ID: O20150210001641 |
News Archive
CompPharma, a consortium of workers' compensation pharmacy benefit managers, has compiled a directory of terms and definitions describing various aspects of the workers' compensation pharmacy industry.
AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02. The company based its fast decision on the first interim analysis of the secondary endpoints at the six month time point.
Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, is working to educate the public about hereditary cancer risk assessment and testing during Prostate Cancer Awareness Month this September.
NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of patient randomization in its Phase 3 registration study of GATTEX® (teduglutide). The double-blind, placebo-controlled safety and efficacy study, which is known as STEPS, is being conducted in patients with parenteral nutrition (PN) dependent short bowel syndrome (SBS) and is now fully randomized with 86 patients.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michelle L Bush, MD 95 Chapel St, Norwood, MA 02062-3155 Ph: (781) 762-5858 | Michelle L Bush, MD 128 Carnegie Row, Norwood, MA 02062-5161 Ph: (781) 762-5858 |
News Archive
CompPharma, a consortium of workers' compensation pharmacy benefit managers, has compiled a directory of terms and definitions describing various aspects of the workers' compensation pharmacy industry.
AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02. The company based its fast decision on the first interim analysis of the secondary endpoints at the six month time point.
Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, is working to educate the public about hereditary cancer risk assessment and testing during Prostate Cancer Awareness Month this September.
NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of patient randomization in its Phase 3 registration study of GATTEX® (teduglutide). The double-blind, placebo-controlled safety and efficacy study, which is known as STEPS, is being conducted in patients with parenteral nutrition (PN) dependent short bowel syndrome (SBS) and is now fully randomized with 86 patients.
› Verified 7 days ago
Raluca Iuster, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 95 Chapel Street, Dermatology Associates, Norwood, MA 02062 Phone: 508-520-3387 | |
Ronald Finn, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 95 Chapel St, Norwood, MA 02062 Phone: 781-762-5858 Fax: 781-949-4343 | |
Jennifer Renee Jenkins, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 128 Carnegie Row, Norwood, MA 02062 Phone: 781-762-5858 | |
Allen I Berliner, MD Dermatology Medicare: Medicare Enrolled Practice Location: 95 Chapel Street, Norwood, MA 02062 Phone: 781-762-5858 Fax: 781-949-4343 | |
Dr. Mina Yaar, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 95 Chapel St, Norwood, MA 02062 Phone: 781-762-5858 Fax: 781-949-4343 | |
Dr. Joan H Spiegel, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 111 Morse St, Brigham And Womens At Norwood, Norwood, MA 02062 Phone: 781-440-3700 | |
Linda Mary Tambascio Gibbons, PA Dermatology Medicare: Accepting Medicare Assignments Practice Location: 95 Chapel St, Norwood, MA 02062 Phone: 781-762-5858 Fax: 781-949-4343 |